Cosopt and Eylea drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cosopt (dorzolamide hydrochloride; timolol maleate) and Eylea (aflibercept). Common drug interactions include visual acuity reduced among females and retinal artery occlusion among males.

The phase IV clinical study analyzes what interactions people have when they take Cosopt and Eylea. It is created by eHealthMe based on reports of 45 people who take the same drugs from the FDA, and is updated regularly.

What is Cosopt?

Cosopt has active ingredients of dorzolamide hydrochloride; timolol maleate. It is often used in glaucoma. eHealthMe is studying from 9,029 Cosopt users. Check the latest studies of Cosopt.

What is Eylea?

Eylea has active ingredients of aflibercept. It is often used in macular degeneration. eHealthMe is studying from 27,868 Eylea users. Check the latest studies of Eylea.

On Jul, 15, 2026

45 people who take Cosopt and Eylea together, and have interactions are studied.

What are the common drug interactions of Cosopt and Eylea, by gender? *:

female:

Visual acuity reduced (reduced clearness of vision)
Eye inflammation
Eye irritation
Eye pain
Inflammation
Interstitial lung disease
Ischaemic stroke (stroke; caused by an interruption in the flow of blood to the brain)
Uveitis (inflammation of the uvea)
Vision blurred
Visual impairment

male:

Retinal artery occlusion (blockage of retinal artery)
Intraocular pressure increased
Corneal oedema (corneal swelling)
Facial pain
Febrile neutropenia (fever with reduced white blood cells)
Sepsis (a severe blood infection that can lead to organ failure and death)
Stomatitis (inflammation of mucous membrane of mouth)
Vision blurred
White blood cell count decreased
Cataract (clouding of the lens inside the eye)

What are the common drug interactions of Cosopt and Eylea, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Visual acuity reduced (reduced clearness of vision)
Eye inflammation
Interstitial lung disease
Intraocular pressure increased
Ischaemic stroke (stroke; caused by an interruption in the flow of blood to the brain)
Sepsis (a severe blood infection that can lead to organ failure and death)
Stomatitis (inflammation of mucous membrane of mouth)
Vitreous floaters (spots before the eyes)
White blood cell count decreased
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)

What are the existing conditions these people have? *

Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 15 people, 33.33%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 7 people, 15.56%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 5 people, 11.11%
Cyclitis (inflammation of the ciliary body (eye)): 3 people, 6.67%
Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 3 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Cosopt and Eylea?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously